Masitinib (Rheumatoid Arthritis) Forecast and Market Analysis


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Masitinib (Rheumatoid Arthritis) Forecast and Market Analysis

  1. 1. Masitinib (Rheumatoid Arthritis) Forecast and Market AnalysisReport Details:Published:November 2012No. of Pages: 46Price: Single User License – US$6995Masitinib (Rheumatoid Arthritis) Forecast and Market AnalysisSummaryGlobalData has released its new PharmaPoint Drug Evaluation report, Masitinib (RheumatoidArthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with theNovember 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaitingapproval such as: Eli Lilly’s anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ’sSYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt todislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven oncethey enter the market.AB Science is developing a novel oral c-Kit inhibitor (tyrosine kinase inhibitor) known as masitinib,or AB101. Inhibition of the c-Kit pathway leads to a decrease in histamine levels, mast cells, andIL-4 production, thus decreasing the allergic response. This antineoplastic drug is currently in aninternational, multicenter, randomized, double-blind, placebo-controlled, three-parallel groupPhase IIb/III clinical trial for RA in the US and Czech Republic.Scope- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatmentguidelines as well as an overview on the competitive landscape.- Detailed information on Masitinib including product description, safety and efficacy profiles aswell as a SWOT analysis.- Sales forecast for Masitinib for the top eight countries from 2011 to 2022.- Sales information covered for the US, France, Germany, the UK, Italy, Spain, Japan andAustralia.Reasons to buy- Understand and capitalize by identifying products that are most likely to ensure a robust return
  2. 2. - Stay ahead of the competition by understanding the changing competitive landscape forrheumatoid arthritis.- Effectively plan your M&A and partnership strategies by identifying drugs with the most promisingsales potential- Make more informed business decisions from insightful and in-depth analysis of Masitinibperformance- Obtain sales forecast for Masitinib from 2011 to 2022 in (the US, France, Germany, the UK, Italy,Spain, Japan and Australia)Get your copy of this report @ points covered in Table of Contents of this report include1 Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 52 Introduction 62.1 Catalyst 62.2 Related Reports 73 Disease Overview 93.1 Etiology and Pathophysiology 93.1.1 Etiology 93.1.2 Pathophysiology 93.1.3 Prognosis 123.1.4 Quality of Life 123.2 Symptoms 134 Disease Management 144.1 Overview 144.2 Diagnosis 144.3 Treatment 175 Competitive Assessment 215.1 Overview 215.2 Strategic Competitor Assessment 216 Opportunity and Unmet Need 236.1 Overview 236.2 Unmet Needs 246.2.1 More rheumatologists in the field and physician knowledge of the disease 246.2.2 More cost-effective therapies through oral formulation and biosimilars 246.2.3 The development of predictive tests and discovery of biomarkers 246.2.4 The discovery of curative therapies 256.2.5 Improved drug safety and efficacy profiles 256.3 Gap Analysis 26
  3. 3. 6.4 Opportunities 276.4.1 Predictive tools for diagnosis and treatment 276.4.2 Target specificity 277 Pipeline Assessment 287.1 Overview 287.2 Promising Drugs in Clinical Development 298 Masitinib (AB101) 318.1 Overview 318.2 Efficacy 328.3 Safety 338.4 Dosing and Formulation 338.5 Potential Clinical Positioning 338.6 Potential Commercial Positioning 338.7 Pricing and Reimbursement 348.8 SWOT Analysis 348.9 Forecast 359 Appendix 369.1 Abbreviations 369.2 Bibliography 389.3 Methodology 419.4 Forecasting Methodology 419.4.1 Diagnosed Rheumatoid Arthritis Patients 419.4.2 Percent Drug-treated Patients 419.4.3 General Pricing Assumptions 429.4.4 Pricing of Pipeline agents 439.5 Physicians and Specialists Included in this Study 439.6 Primary Research - Prescriber Survey 449.7 About the Authors 449.7.1 Analysts 449.7.2 Global Head of Healthcare 459.8 About GlobalData 469.9 Contact Us 469.10 Disclaimer 461.1 List of TablesTable 1: Symptoms of Rheumatoid Arthritis 13Table 2: Treatment Guidelines for Rheumatoid Arthritis 17Table 3: Top Three Biologics Prescribed for Moderate-Severe Rheumatoid Arthritis by Market 20Table 4: Treatment Guidelines for Rheumatoid Arthritis 22Table 5: Overall Unmet Needs - Current Level of Attainment 23Table 6: Clinical Unmet Needs - Gap Analysis, 2012 26Table 7: Rheumatoid Arthritis - Phase Pipeline, 2012 29
  4. 4. Table 8: Comparison of Therapeutic Classes in Development for RA, 2012 30Table 9: Product Profile - Masitinib 31Table 10: ACR Responses for Masitinib in the ITT Population (12 Weeks) 32Table 11: ACR Responses for Masitinib in the ITT Population (12-82 Weeks) 32Table 12: Masitinib SWOT Analysis, 2012 34Table 13: Global Sales Forecasts ($m) for Masitinib 35Table 14: Physicians Surveyed, By Country 441.2 List of FiguresFigure 1: Healthy and Arthritic Joint with Rheumatoid Arthritis 9Figure 2: Rheumatoid Arthritis Biologic Drug Targets 11Figure 3: Diagnosis Criteria for Rheumatoid Arthritis Based on 2010 ACR/EULAR Criteria PointSystem 16Figure 4: Severity of Rheumatoid Arthritis 16Figure 5: Biologic Treatment Flow Based on Updated 2012 ACR Treatment Recommendations*19Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2012-2022 29Contact: for more information.